Oncolytic herpes sim plex virus (HSV) can replicate in and kill cancer cells without harming normal tissue. G47驻 is a third鄄 generation HSV vector. In this study, the therapeutic effects of G47驻 on human nasopharyngeal carcinoma (NPC) were determined in vitro and in vivo. The human NPC cell lines CNE鄄 2 and SUNE鄄 1, primary normal nasopharyngeal epithelial cells (NPECs), and immortalized nasopharyngeal cells NP鄄 69 and NPEC2/Bmi1 were infected with G47驻 at different multiplicities of infection (MOIs). The survival of infected cells was observed daily. Two subcutaneous models of NPC were established with CNE鄄 2 and SUNE鄄 1 in Balb/c nude mice. G47驻 or virus buffer as control was injected into the subcutaneous tumors. Tumor size was measured twice a week, and animals were euthanized when the diameter of their tumors exceeded 18 mm or when the animals appeared moribund. For the NPC cell lines CNE鄄 2 and SUNE鄄 1, more than 85% and 95% of cells were killed on day 5 after G47驻 infection at MOI = 0.01 and MOI = 0.1, respectively. Similar results were observed for an immortalized cell line NPEC2/Bmi鄄 1. A moderate effect of G47驻 was also found on another immortalized cell line NP鄄 69, of which only 27.7% and 75.9% of cells were killed at MOI = 0.01 and MOI = 0.1, respectively. On the contrary, there was almost no effect observed on NPECs. The in vivo experiments showed that tumors in mice in the G47驻鄄 treated group regressed completely, and the mice exhibited much longer survival time than those in the control groups. Our results suggest that the potential therapeutic effects of G47驻 would be applicable for treatment of NPC patients in the future.
Original Article
Nasopharyngeal carcinoma (NPC) is a unique malignant head and neck cancer that has been recognized for over 100 years. It arises from the mucosal epithelium lining the upper part of the pharynx behind the nasal cavities. NPC is one of the most poorly understood and commonly misdiagnosed malignancies [1] . Rarely reported in the West, NPC occurs at high frequency in southern China and Southeast Asia, where the annual incidence is more than 20 cases per 100 000 individuals [1, 2] . Its frequency is very high in the Guangzhou area, where the annual incidence reaches 25 cases per 100 000 [3] . The reason for this geographic distribution remains unclear.
Possible reasons are dietary factors (consumption of traditional preserved food), strong association with the EpsteinBarr virus (EBV), and genetic predisposition [3, 4] . The 5year overall survival rates of NPC were 95% to 70% , 83% to 65% , 76% to 54% , and 56% to 29% for patients with stages I, II, III, and IV tumor, respectively, according to the data of the American Joint Committee on Cancer (AJCC) staging system [57] . Because the nasopharynx is surrounded by critical organs, it is difficult to surgically excise nasopharyngeal tumors. Surgery is usually offered only when there is evidence of local recurrence or persistent disease. NPC is highly radiosensitive. Currently available therapeutic approaches for NPC are either radiotherapy alone or chemoradiotherapy, which combines the effectiveness of Jia鄄 Ni Wang et al.
Anti鄄 tumor effects of G47delta on NPC chemotherapy on distant metastases and radiotherapy on local disease [8] . Patients with an early stage disease have a high cure rate after radiotherapy [8] . Chemoradiotherapy has been shown to improve local control, diseasefree survival, and overall survival rates for patients with primary stage NPC [913] . However, the prognosis remains poor in a significant number of patients with late stage diseases [1417] . Although NPC is more radiosensitive compared with other head and neck carcinomas, the high frequency of local recurrences and distant metastasis resulted in the 5year overall survival rate from 32% to 52% [13] . A high rate of treatment failure is observed in patients with advanced NPC. Most NPC patients have advanced disease at the time of diagnosis because of the insidious clinical symptoms, difficulty of examination, and relatively poorly accessible anatomic location of the nasopharynx. In addition, longterm side effects of radiotherapy and chemotherapy are obvious and include secondary malignancies [18] . Thus, there is an intense need for specific therapies that effectively target NPC itself rather than those associated with the damage to normal tissue.
When evaluating novel therapeutic strategies for NPC, the two most highly desirable features are (1) the ability to destroy the tumor without harming normal tissue and (2) the ability to activate the antitumor immune responses to seek and kill covert tumors. Oncolytic HSV, which is designed to be inherently cytotoxic to tumor cells, seems to meet these criteria. The spread of the vector is confined to tumor cells and spares normal cells, leading to minimal toxicity to normal tissue [19] . Spread of the vector can also trigger a tumorspecific immune response. The selfperpetuating nature of oncolytic HSV allows a small amount of input virus to amplify after several cycles of replication until the target cells are destroyed. Therapeutic transgenes can also be transferred to the tumor. As these viruses kill tumor cells mainly by oncolysis, they do not have crossresistance with other therapeutic strategies such as radiotherapy and chemotherapy. Therefore, it is practical to combine viral therapy with other therapeutic approaches for enhanced effectiveness.
Since the first report of the successful treatment of a brain tumor model by an oncolytic HSV vector in 1991 [20] , researchers have focused on the development of increasingly efficacious and safe oncolytic HSV vectors. A variety of oncolytic HSV vectors have been developed, and several among these (e.g., G207, 1716, NV1020, and OncoVex GMCSF) have safely completed phase I clinical trials involving patients with various solid tumors [2126] . G47驻 , the vector used in this study, is a thirdgeneration oncolytic HSV vector. It is a multigene mutant of that contains three main mutations ( , , and ), which results in its selective cytotoxicity to tumor cells. The major determinant of neurovirulence is 34.5 [27] . G47Δ also precludes the shutoff of host protein synthesis in host cells [28] , which guarantees the confined replication of the virus only in tumor cells. The ( ) gene encodes a subunit of viral ribonucleotide reductase, which is the key enzyme for DNA synthesis in nondividing cells [29, 30] . Without this enzyme, DNA replication is blocked in normal cells [31] . Insertion of the gene inactivates the gene. Notably, mutation of makes the virus more sensitive to the drugs acyclovir and ganciclovir [32] , which augments the safety of the virus as a clinical therapy. Although the mutations of and confer significant safety attributes [30] , they attenuate viral growth. Mutation of can enhance antitumor activities because it places the late gene under control of the immediateearly promoter, which induces the amplification of mutant growth. Furthermore, the gene binds to the antigen presentation transporter (TAP) protein and blocks peptide loading of major histocompatibility complex (MHC) class I molecules [33] . This deletion of increases MHC class I presentation, thus enhancing stimulation of lymphocytes and decreasing NK cytolysis of host cells [34, 35] . These important features of oncolytic HSV G47Δ enhanced its antitumor immune responses when treating advanced tumors, especially those with few treatment options.
In the present study, we evaluated the cytotoxic effects of G47Δ on two human NPC cell lines, two immortalized human nasopharyngeal cell lines , and one primary cultured normal nasopharyngeal cell line. Furthermore, we evaluated the therapeutic effects of G47Δ in xenograft models of two human NPC cell lines.
Materials and Methods

Cells and viruses
Two poorly differentiated NPC cell lines, CNE2 and SUNE1, were cultured in RPMI1640 with 4.5 g/L glucose (Mediatech, Inc., Herndon, VA) supplemented with 10% fetal calf serum (Hyclone Laboratories, Logan, UT) at 37益 in an atmosphere of 5% CO 2 .
Immortalized nasopharyngeal cell lines NP69 (obtained from Dr. George SW Tsao, Cancer Center, Hong Kong University, Hong Kong) and NPEC2/Bmi1, as well as primary NPECs were cultured in keratinocyte/serumfree medium (Invitrogen, Grand Island, NY) at 37益 in an atmosphere of 5% CO 2 [36] . African green monkey kidney Vero cells (purchased from the Committee on Type Culture Collection of Chinese Academy of Sciences, Shanghai, China) were cultured in Dulbecco爷s modified Eagle medium (DMEM) with 4.5 g/L glucose (M ediatech, Inc.) supplemented with 10% fetal calf serum (Hyclone Laboratories, Logan, UT) at 37益 in an atmosphere of 5% CO 2 .
Oncolytic HSV G47Δ was provided by MediGene, Inc. (San Diego, CA). Viruses were multiplied in monolayer cultures of Vero cells in DMEM containing 3% inactivated fetal calf serum at 34.5益 . First, G47Δ was diluted in phosphatebuffered saline (PBS) containing 1% inactivated fetal calf serum. Vero cells were then infected at multiplicities of infection (MOIs) of 0.02 to 0.03 and incubated at 37益 in an atmosphere of 5% CO 2 for 90 min. Viral inoculums were removed and DMEM containing 3% inactivated fetal calf serum was added. The cells were placed in a 34.5益 incubator with an atmosphere of 5% CO 2 for 2 to 3 days until most cells became rounded and refractile. The infected cells were harvested and resuspended in a 1:1 mix of DMEM (no serum) and virus buffer (150 mmol/L NaCl/20 mmol/L Tris at pH 7.5). The cell suspension was rapidfrozen in ethanol/dry ice and thawed 3 times to lyse cells and release viruses. The cell debris was removed by lowspeed centrifugation (2000 × for 10 min at 4益 ). G47Δ was titrated into Vero cells by plaque assay.
In vitro cytotoxicity
All cell types were seeded separately into 6well plates at a density of 1 伊 10 5 cells per well. When the 6well plates were 50% covered, the cells were infected with G47Δ at MOIs of 0.01 and 0.1, whereas controls were mockinfected with PBS. After 24 h of incubation at 37益 , the number of surviving cells was counted with a hemocytometer daily for 5 days. Average numbers of cells from duplicate wells are plotted as percentages of the mock wells. To eliminate floating cells before counting, the plates were washed with 1 mL of PBS twice before adding trypsin. Xgal staining was performed daily to visualize the infected cells.
X鄄 gal histochemistry
On days 1 to 5 postinfection, the medium was removed and the cells were fixed with 0.2% glutaraldehyde/2% paraformaldehyde for 5 min. They were then incubated with Xgal substrate solution (PBS at pH 7.2 containing 0.5 mg/mL 5bromo4chloro3 indolyl茁 Dgalactopyranoside, 5 mmol/L potassium ferricyanide, 5 mmol/L potassium ferrocyanide, and 2 mmol/L magnesium chloride) at 37益 for 2 h. The cells showing blue staining were considered Xgal positive cells.
Animal studies
Fourweekold female Balb/c nude mice were purchased from the Shanghai Institutes for Biological Sciences (Chinese Academy of Sciences, Shanghai, China) and bred with 5 mice in each cage. All animal procedures were approved by the Animal Care and Use and Institute Research Ethics Committees of Sun Yatsen University. The mice were monitored daily for palpable tumor formation, and tumors were measured by a Vernier caliper (length and width were represented by and , respectively) and the mice were weighed twice a week.
Subcutaneous tumor treatment
Poorly differentiated NPC CNE2 cells (1 伊 10 6 ) and SUNE1 cells (5 伊 10 5 ) were suspended in 100 滋 L of RPMI1640 complete culture with 25% Matrigel (BD Biosciences) and implanted subcutaneously into the left flanks of 4weekold nude mice. When the maximal diameter of the subcutaneous tumors was approximately 5 mm, the tumor were injected twice a week for 2 weeks with 2 伊 10 7 pfu/50 滋 L of G47Δ or virus buffer (150 mmol/L NaCl and 20 mmol/L Tris at pH 7.5) as control. Tumor size was measured by Vernier calipers, and tumor volume was calculated with the formula = 伊 2 /2, where represents tumor volume and and represent length and width, respectively. Animals were euthanized when the maximal diameter of their tumors exceeded 18 mm or when the animals appeared moribund as characterized by a rough hair coat, lethargy, hunched posture, recumbent posture, or limited ambulatory movements in response to stimulation; this was recorded as the end point for survival studies. For histological hematoxylin and eosin staining, the excised subcutaneous tumors were fixed in formaldehyde and embedded in paraffin.
Virus biodistribution studies
CNE2 and SUNE1 subcutaneous NPC model mice were treated 4 times with 2 伊 10 7 pfu/50 滋 L of G47驻 . The subcutaneous tumors were excised and embedded with optimum cutting temperature (OCT) compound. Cryostat sections (10 滋 m thick) were cut and fixed with 2% paraformaldehyde in PBS for 10 min and then washed thoroughly with PBS 3 times. Following incubation with PBS containing 2 mmol/L magnesium chloride, 0.01% sodium deoxycholate, and 0.02% NP40 for 10 min at 4益, the sections were stained with Xgal substrate solution (PBS at pH 7.2 containing 1 mg/mL 5 bromo4chloro3indolylhDgalactopyranoside, 5 mmol/L potassium ferricyanide, 5 mmol/L potassium ferrocyanide, 2 mmol/L magnesium chloride, 0.01% sodium deoxycholate, and 0.02% NP40) at 34益 for 4 h. Sections were washed with PBS containing 2 mmol/L EDTA and counterstained with eosin before mounting.
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Statistical analyses
Statistical analyses were performed using SPSS 13.0. Differences among variables were assessed by the logrank test. A value less than 0.05 was considered significant.
Results
In vitro cytotoxicity
To assess the cytotoxicity of oncolytic HSV vector G47Δ
, monolayers of human NPC cell lines CNE2 and SUNE1, immortalized nasopharyngeal cell lines NP69 and NPEC2/Bmi1, and NPECs were infected with G47Δ at low MOIs (MOI = 0.01 and MOI = 0.1, Figure 1 ). For the NPC cell line CNE2, more than 85% and 95% of cells were killed by G47Δ at MOI = 0.01 and MOI = 0.1, respectively, on day 5 after infection ( Figures 1A and 1C) , and 100% of SUNE1 cells in the MOI = 0.01 and MOI = 0.1 groups were killed on day 5 (Figures 1B and 1D ). For the immortalized nasopharyngeal cell line NPEC2/Bmi1, an effect similar to that in the NPC cell lines was observed; more than 95% and 100% of cells were killed by G47Δ at MOI = 0.01 and MOI = 0.1, respectively, on day 5 after infection ( Figure 2 ). G47Δ had a moderate effect in Figure 2E ). On the contrary, NPECs were viable and intact even 5 days after infection ( Figure 2F ). Because G47Δ contains the transgene in the ICP6 region, infected cells could be histochemically stained by Xgal. The infected cells and the spread of G47Δ were illustrated by blue staining ( Figures 1A and 2B , and 2AC).
Anti鄄 tumor effects of G47驻 in NPC xenografts
For the studies, CNE2 and SUNE1 cells were implanted in the left flanks of female Balb/c nude mice. The tumors were then injected with G47Δ (2 伊 10 7 pfu, 4 times) when they became palpable (approximately 5 mm in diameter). To evaluate G47Δ replication , G47Δ treated tumorbearing mice were euthanized, and Xgal histochemistry were performed on sectioned subcutaneous tumors to detect G47Δinfected cells. The blue staining represented the replication of G47驻 . Coronal sections through a subcutaneous tumor of a nude mouse 24 h ( Figures 3A and 3D ), 3 days ( Figures  3B and 3E) , and 6 days ( Figures 3C and 3F ) after G47Δ injection illustrate G47Δ replication in the subcutaneous tumors.
The subcutaneous tumor volume increased obviously within a few days in the mocktreated group, whereas in the G47Δ treated group, the tumor regressed gradually or even disappeared in both the CNE2 ( Figures 4A, 4C , 4E, and 4G ) and SUNE1 ( Figures 4B, 4D , 4F, and 4H) groups. The mice in the G47Δ treated CNE2 or SUNE1 groups did not appear A, monolayers of NPEC2/Bmi1 cells in 6鄄 well dishes were infected with G47驻 or mock infected and incubated with DMEM containing 1% heat鄄 inactivated FBS at 37益. On the following 5 days after infection, the cells were stained with X鄄 gal solution. Infected cells (expressing lacZ) were stained with X鄄 gal (blue). B, X鄄 gal staining of NP鄄 69 cells infected with G47驻 . C, X鄄 gal staining of NPECs infected with G47驻 . Monolayers of NPEC2/Bmi1 (D), NP鄄 69 (E), and NPECs (F) in 6鄄 well plates were infected with G47驻 (MOI = 0.01 and MOI = 0.1), incubated in DMEM containing 1% heat鄄 inactivated FBS at 37益, and counted on a Coulter counter on the days indicated. The average numbers of cells from duplicate wells are plotted as percentage of the mock鄄 infected cells. Jia鄄 Ni Wang et al. Anti鄄 tumor effects of G47delta on NPC moribund, so they were euthanized on days 60 and 80, respectively; however, the median survival times of mocktreated mice were 20 ( 字 2 = 11.74, < 0.001, logrank test) and 50 days ( 字 2 = 10.74, < 0.001, logrank test), respectively (Figures 5 and 6) . The difference of CNE2 tumor volume between the mocktreated groups and the virustreated groups was obvious with the elapse of time ( Figure 5 ). The difference of SUNE1 tumor volume between the mocktreated groups and the virustreated groups was obvious with the elapse of time (Figure 6 ).
Discussion
In this study, we investigated the cytotoxic effects of the thirdgeneration oncolytic HSV G47Δ on normal NPECs, immortalized nasopharyngeal cells, and NPC cells. G47Δ effectively killed human NPC cells and immortalized nasopharyngeal cells but not normal nasopharyngeal cells
. We then demonstrated its therapeutic value in the treatment of NPC through animal experimentation. Intratumor injection of G47Δ induced an obvious therapeutic effect and effectively prolonged the survival of treated mice bearing NPC tumors.
NPC is one of the most highly prevalent and harmful malignant head and neck tumors. It occurs sporadically in most Western countries but has a high incidence in southern China, Hong Kong, Taiwan, Singapore, and Malaysia [37] . The worldwide incidence of NPC exceeds 80 000 cases per year [38] . The available therapeutic options for NPC include surgery, brachytherapy, radiosurgery, stereotactic RT, and IMRT, each with or without cisplatinbased chemotherapy. NPC is relatively radiosensitive and occurs in an anatomic location that is poorly accessible to surgeons. Therefore, highdose radiotherapy combined with chemotherapy has long been the mainstay of therapy modalities and is a primary component of curativeintent treatment for nondisseminated NPC [9, 39] . The standard medicine used in chemotherapyradiotherapy is cisplatin, which, when used in the combined treatment approach, procides a benefit for overall survival and improves both local and distant control. However, the survival advantages of cisplatinbased chemotherapy alone has not been verified for NPC [39] . Patients presenting an early stage NPC have a high cure rate after radiotherapy. Unfortunately, NPC patients tend to present advanced stage diseases with highly metastatic potential because the anatomic site of the tumor is cryptic and the disease is usually asymptomatic at early stages.
Despite advances in radiotherapy technology, patients with NPC have not experienced any fundamental improvements in survival rate or prognosis, Figure 3 .
A -C, coronal sections of CNE鄄 2 subcutaneous tumor in a nude mouse 24 h, 3 days, and 6 days after G47驻 (2 伊 10 7 pfu) injection illustrate the G47驻 replication, respectively. Sections were stained with X鄄 gal solution to identify cells containing replicating G47驻 (blue) and counterstained with eosin. D-F, coronal section of SUNE鄄 1 subcutaneous tumor in a nude mouse 24 h, 3 days, and 6 days after G47驻 (2 伊 10 thus prompting the development of novel therapeutic strategies. An ideal therapeutic modality should have both good tumor specificity and high killing efficacy with wellproven safety. Recent studies indicate that engineered oncolytic viruses represent a new modality for malignant tumor treatment. Indeed, these oncolytic viruses have shown highly promising results in clinical trials [40] . Therefore, progress in this field is gaining momentum.
Since the 1990s, oncolytic viruses have been utilized to treat patients with malignant carcinoma from phase I to phase III trials. Several kinds of oncolytic viruses were used for the treatment of NPC. These include VSVΔ 51 (vesicular stomatitis virus), which can be further augmented when combined with ionizing radiation [41] , and H101 (adenovirus), which has already finished clinical trials and been formally approved by the State Food and Drug Administration (SFDA) [4245] . However, there are few reports about the utilization of oncolytic HSV in the treatment of human NPC.
HSV1 is an enveloped, doublestranded DNA virus with a genome size of approximately 152 kb. HSV1 vectors target actively dividing tumor cells whereas sparing adjacent normal cells, making them a possible therapy for selective tumor destruction. The infected tumor cells are destroyed by the replication of oncolytic HSV1, which releases many progeny virions. Viral amplification and lateral transmission result in further destruction of surrounding tumor cells until tumor cells are totally destroyed. Because this kind of virus kills tumor cells by oncolysis, it does not have crossresistance with other therapeutic options such as radiotherapy and chemotherapy and thus can serve as a complementary approach to these therapeutic modalities.
NPC is typically heterogenous, surgically inaccessible, and resistant to some single agent chemotherapies. Although radiotherapy is effective to some extent, there is evidence of radiotherapy treatment failure, and radiotherapyrelated injury and oncogenicity are common. Therefore, no single therapy is completely effective for NPC treatment. Nevertheless, oncolytic HSV1 vectors are different from routine treatment modalities like chemotherapy and radiotherapy and thus provide an additional approach for treatment.
Unlike chemotherapy and radiotherapy, oncolytic HSV1 is not limited by tumor stage or patient health CNE鄄 2 SUNE鄄 1 Figure 5 . status. Furthermore, the viral genes affecting neuropathogenicity are knocked down in HSV1, reducing the potential for severe illness. In addition, other antiviral agents, such as acyclovir and ganciclovir, can effectively shut off viral replication, so this kind of therapy approach will not lead to highdose toxicities. These features suggest wide application and bright prospects of oncolytic HSV in the treatment of NPC. The antitumor effect of G47Δ has been verified in several kinds of malignant tumors, including glioblastoma [46] , schwannoma tumor [47] , prostate cancer [48, 49] , and breast cancer [50] . Recently, G47 Δ has entered phase I clinical trial for progressive glioblastoma.
Because of their anatomic location and proximity to crucial adjacent organs, NPCs require a highly selective antitumor therapy. Thus, it was very important to show that G47Δ confines replication to dividing cells without damaging normal cells. Therefore, we established primary cultured NPECs to test their affinity to G47Δ .
Our results showed that the normal NPECs were intact even 5 days postG47Δ infection, which indicated the safety of G47Δ . However, the cytotoxic effects in the NPC cell lines CNE2 and SUNE1 were obviously observed. This data suggest that G47Δ is a safe and valid as a novel biological therapy.
Immortalization and bypass of senescence are considered early steps in tumor development. In this study, we also observed that G47Δ had cytotoxicity effects at a very low MOI in two different immortalized NPEC lines, indicating that G47Δ may function effectively in the early stages of tumorigenesis. Because the injection of G47Δ does not pose any potential health hazard, G47Δ could probably be used as a preventive agent against premalignant diseases in patients with a high risk of NPC.
To investigate the antitumor effect of G47Δ on NPC, we established a subcutaneous model of NPC using two different cell lines, CNE2 and SUNE1. G47Δ was administered twice a week without any observable toxicity in the animals. In the virustreated group, a higher survival rate and significant reduction in tumor growth were noted after therapy. The subcutaneous tumors of all treated mice gradually regressed in both the CNE2 and SUNE1 groups, suggesting that G47Δ has potential as a treatment to effectively inhibit different types of NPC tumors.
Although we observed cytotoxicity effects of G47Δ on immortalized NPEC lines, we have yet to explore the underlying mechanism of these effects. In addition, the limited types of NPC cell lines used in this study may have encumbered the stringency of the effectivity for G47Δ in the treatment of NPC. Thus, to fully test the antitumor effects of G47Δ , another clinical study with a larger cohort of samples should be performed.
In conclusion, oncolytic HSV vector G47Δ was effective in both immortalized nasopharyngeal cells and NPC cells but spared normal NPECs. This feature of restricted replication gives it potential as both a therapeutic and preventive agent for human NPC. Direct intratumoral inoculation of G47Δ induced an obvious therapeutic effect on NPC, suggesting G47Δ may be useful in future clinical applications in cancer therapy. 
